We routinely produce Copper-67 (Cu-67) to ensure expanded and reliable supply of this promising radioisotope for the treatment of patients with cancer. Explore what lies ahead for radioisotope manufacturing in Beloit, Wisconsin.
ISOTOPE PROCESSING FACILITY
Our isotope processing facility features our chemical processing line and is currently producing Copper-67 (Cu-67) in limited quantities. NorthStar is investing to upscale this process and equipment for large commercial quantities. In addition, this facility includes our analytical testing laboratory and additional hot cells for future isotope processing.
Accelerator Production Facility
We are currently irradiating and investing to expand our groundbreaking technology to produce Copper-67 (Cu-67) from Zinc-68 (Zn-68) using electron beam accelerators. NorthStar’s unique and proprietary electron accelerator production facility and processes are designed to provide efficiencies throughout the production process, thereby enabling the production of multiple radioisotopes utilizing the same equipment.
ACTINIUM-225 PRODUCTION FACILITY
We continue our investment in groundbreaking technology to produce non-carrier added Actinium-225 (n.c.a. Ac-225) from Radium-226 (Ra-226) using our electron beam accelerators. There are several technologies used to produce Ac-225 but none that can scale to meet commercial quantities. NorthStar’s method is capable of meeting customer demand. Our stand-alone facility, currently under construction, will fully house our dedicated electron beam accelerator, chemical processing line and all analytical laboratory capabilities.
NorthStar’s Radiopharmaceutical CDMO/CMO unit offers customized services and expertise to accelerate biopharmaceutical companies’ development and commercialization programs. The NorthStar CDMO is the first and only U.S. facility providing commercial-scale, multi-radioisotope production and radiopharmaceutical development all on the same campus. With a 52,000 sq. ft. footprint, it sets new industry standards, serving the growing therapeutic and diagnostic radiopharmaceuticals market. Our facility effectively supports the entire product lifecycle, cGMP manufacturing suites, one EU compliant manufacturing suite and radiation safety programs to ensure high-quality and safe practices.